Bispecific T-cell engagers are emerging as promising treatment options for patients with heavily pretreated multiple myeloma and B-cell lymphomas, especially for patients with disease relapse following CAR T-cell therapy. Careful monitoring of adverse events and implementing appropriate supportive care strategies is important to maximize the clinical benefit associated with bispecific T-cell engager therapy.

Clinicians are challenged to remain up-to-date about the treatment advances that will enable them to make informed decisions to optimize the clinical outcome of patients with relapsed/refractory disease.

Clinicians are challenged to remain up-to-date about the treatment advances that will enable them to make informed decisions to optimize the clinical outcome of patients with relapsed/refractory disease.

Educating clinicians about the recent clinical advances and the benefits/risks associated with the use of transplant and CAR T-cell therapy can help them to make informed clinical decisions for individual patients.

The selection of optimal second-line therapy for mantle cell lymphoma (MCL) depends on the age and fitness of the patients as well as the eligibility for transplant or CAR T-cell therapy. In the absence of standard management, patients with relapsed/refractory MCL should be referred for participation in prospective clinical trials investigating novel treatment regimens.

Pharmacists play a critical role in patient education, monitoring, and management of treatment-related toxicities and would benefit from a comprehensive review of the novel treatments for indolent non-Hodgkin lymphomas.

Pharmacists play a critical role in patient education, monitoring, and management of treatment-related toxicities and would benefit from a comprehensive review of the novel treatments for indolent non-Hodgkin lymphomas.

Oncologists and hematologists need to maintain high awareness of the recently approved targeted therapies and the precise indications for their use so that these can be incorporated in routine clinical practice in the appropriate patient population.

The information presented in this talk will address the long-term effects of CAR T-cell therapy, including HLH/MAS, B-cell aplasia, and prolonged cytopenias. Nurses will learn how to recognize signs/symptoms of these effects and how to manage them in order to educate patients and provide ideal care to patients undergoing CAR T-cell therapy.